Rachael L Terry
Overview
Explore the profile of Rachael L Terry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1739
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meyran D, Zhu J, Butler J, Tantalo D, MacDonald S, Nguyen T, et al.
Sci Transl Med
. 2023 Apr;
15(690):eabk1900.
PMID: 37018415
Patients who receive chimeric antigen receptor (CAR)-T cells that are enriched in memory T cells exhibit better disease control as a result of increased expansion and persistence of the CAR-T...
2.
Fleuren E, Terry R, Meyran D, Omer N, Trapani J, Haber M, et al.
Biomedicines
. 2021 Dec;
9(12).
PMID: 34944614
Despite aggressive surgery, chemotherapy, and radiotherapy, survival of children and adolescents and young adults (AYAs) with sarcoma has not improved significantly in the past four decades. Immune checkpoint inhibitors (ICIs)...
3.
Terry R, Meyran D, Fleuren E, Mayoh C, Zhu J, Omer N, et al.
Cancers (Basel)
. 2021 Sep;
13(18).
PMID: 34572932
Sarcomas are a diverse group of bone and soft tissue tumors that account for over 10% of childhood cancers. Outcomes are particularly poor for children with refractory, relapsed, or metastatic...
4.
McDonald M, Khoo W, Ng P, Xiao Y, Zamerli J, Thatcher P, et al.
Cell
. 2021 Apr;
184(7):1940.
PMID: 33798441
No abstract available.
5.
McDonald M, Khoo W, Ng P, Xiao Y, Zamerli J, Thatcher P, et al.
Cell
. 2021 Feb;
184(5):1330-1347.e13.
PMID: 33636130
Osteoclasts are large multinucleated bone-resorbing cells formed by the fusion of monocyte/macrophage-derived precursors that are thought to undergo apoptosis once resorption is complete. Here, by intravital imaging, we reveal that...
6.
Terry R, Meyran D, Ziegler D, Haber M, Ekert P, Trapani J, et al.
J Clin Invest
. 2020 Jun;
130(7):3391-3402.
PMID: 32538896
Pediatric cancers, particularly high-risk solid tumors, urgently need effective and specific therapies. Their outlook has not appreciably improved in decades. Immunotherapies such as immune checkpoint inhibitors offer much promise, but...
7.
Khoo W, Ledergor G, Weiner A, Roden D, Terry R, McDonald M, et al.
Blood
. 2019 Apr;
134(1):30-43.
PMID: 31023703
The era of targeted therapies has seen significant improvements in depth of response, progression-free survival, and overall survival for patients with multiple myeloma. Despite these improvements in clinical outcome, patients...
8.
Chai R, McDonald M, Terry R, Kovacic N, Down J, Pettitt J, et al.
Oncotarget
. 2017 Oct;
8(40):68047-68058.
PMID: 28978095
Melphalan is a cytotoxic chemotherapy used to treat patients with multiple myeloma (MM). Bone resorption by osteoclasts, by remodeling the bone surface, can reactivate dormant MM cells held in the...
9.
McDonald M, Reagan M, Youlten S, Mohanty S, Seckinger A, Terry R, et al.
Blood
. 2017 May;
129(26):3452-3464.
PMID: 28515094
Multiple myeloma (MM) is a plasma cell cancer that develops in the skeleton causing profound bone destruction and fractures. The bone disease is mediated by increased osteoclastic bone resorption and...
10.
Lawson M, McDonald M, Kovacic N, Khoo W, Terry R, Down J, et al.
Nat Commun
. 2015 Dec;
6:8983.
PMID: 26632274
Multiple myeloma is largely incurable, despite development of therapies that target myeloma cell-intrinsic pathways. Disease relapse is thought to originate from dormant myeloma cells, localized in specialized niches, which resist...